您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > Galanin(1-30)(human)
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Galanin(1-30)(human)
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Galanin(1-30)(human)图片
CAS NO:119418-04-1
包装与价格：
包装价格(元)
500μg电议
1mg电议
5mg电议

产品介绍
Galanin (1-30) (human) 是一种 30 个氨基酸的神经肽，作为\u200b\u200b GalR1 和 GalR2 受体的激动剂，Kis 均为 1 nM。
Cas No.119418-04-1
别名甘丙肽
化学名(2S,3Z,5S,6Z,8S,9Z,12Z,14S,15Z,17S,18Z,20S)-17-(4-aminobutyl)-20-((Z)-((1Z,3S,4Z,6S,7Z,9S,10Z,13Z,15S,16Z,18S,19Z,21S,22Z,24S,25Z,27S,28Z,30S)-3,18-bis((1H-imidazol-5-yl)methyl)-1-((S)-1-((3Z,5S,6Z,8S,9Z,11S,12Z,15Z,17S,18Z,20S,21Z,23S,24Z,26S,27Z,29S,30Z
Canonical SMILESCC(C[C@@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/C/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/CN)([H])CC1=CNC2=CC=CC=C12)([H])[C@@](O)([H])C)([H])CC(C)C)([H])CC(O)=N)([H])CO)([H])C)([H])CC3=CC=C(O)C=C3)([H])CC(C)C)([H]
分子式C139H210N42O43
分子量3157.41
溶解度Soluble to 0.50 mg/ml in Water
储存条件-20°C, protect from light
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Galanin (1-30), human is a 30-amino acid neuropeptide, and acts as an agonist of GalR1 and GalR2 receptors, with Kis of both 1 nM.

Galanin (1-30), human (Gal1-30) is an agonist of GalR1 and GalR2 receptors, with Kis of both 1 nM[1]. Galanin (1-30), human displaces 125I-labeled rat galanin with a Kd of 0.5 nM. Galanin (1-30), human (hGal) causes contractions of isolated longitudinal rat fundus strips, with an ED50 of 13.8 ± 1.6 nM[2].

References:
[1]. Hua XY, et al. Galanin acts at GalR1 receptors in spinal antinociception: synergy with morphine and AP-5. J Pharmacol Exp Ther. 2004 Feb;308(2):574-82.
[2]. Schmidt WE, et al. Isolation and primary structure of pituitary human galanin, a 30-residue nonamidated neuropeptide. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11435-9.